Why MDMA therapy for alcohol use disorder? And why now?

The paper opens by describing alcohol use disorder (AUD) as a major clinical, social and economic problem. Although many people drink without harm, a substantial minority drink in harmful ways (about 24% of adults in England are reported to consume alcohol harmfully) and several percent meet diagnostic criteria for AUD. The disorder commonly co-occurs with depression, anxiety and a history of psychological trauma, and imposes large costs on families and society. Current pharmacological and psychotherapeutic treatments are characterised as unsatisfactory, with high relapse rates after detoxification. Against this background, the author argues that renewed interest in psychedelic-assisted psychotherapy provides a rationale to consider 3,4-methylenedioxymethamphetamine (MDMA) as a potential adjunct for treating AUD. The paper situates the idea historically—classical psychedelics such as LSD were trialled in the 1950s–60s for alcoholism with mixed but sometimes promising results—and notes contemporary research revisiting psychedelic therapies for substance use disorders. MDMA has been used in clinical research for PTSD but, according to the extracted text, has not been formally explored as a treatment for any substance use disorder. The paper therefore sets out a rationale for MDMA-assisted psychotherapy in AUD and describes a planned safety and feasibility study (the Bristol-Imperial MDMA-for-Alcoholism, BIMA, study). An underlying premise is that MDMA's psychopharmacological profile may make it particularly suitable for enabling patients to process traumatic memories without being overwhelmed by negative affect, which is relevant because trauma is common in people with AUD.

This paper is a narrative review and argument rather than a report of a completed randomised clinical trial. The author reviews historical and contemporary literature on psychedelic therapies for substance use disorders, summarises what is known about MDMA's pharmacology and tolerability, and outlines a proposed clinical study (BIMA). The paper references early uncontrolled and randomised LSD studies from the 1950s–60s and later meta-analytic work that pooled those trials; it also summarises reports of ketamine-assisted psychotherapy from the 1990s in Russia. Regarding the proposed BIMA study, the extracted text describes a safety and feasibility design enrolling alcohol-dependent participants who have recently undergone medical detoxification. Participants are to receive an 8-week course of supportive psychotherapy incorporating elements of Motivational Enhancement Therapy, with the majority of sessions being non-drug face-to-face therapy. On two occasions, spaced two weeks apart, participants will receive open-label MDMA-assisted therapy. Each drug-assisted session will use an initial dose of 125 mg MDMA followed, two hours later, by a booster dose of 62.5 mg. Vital signs (including blood pressure and body temperature) will be monitored during the session; participants will remain overnight in the treatment centre and mood and suicide risk will be monitored daily for a week. Follow-up is planned for 9 months post-detox with outcome measures including safety and tolerability, quality of life, physical and mental health status, and drinking behaviours. The extracted text does not clearly report a sample size or detailed statistical analysis plan for the proposed study. The paper also discusses MDMA's pharmacology in narrative terms, noting a lack of scientific consensus and describing MDMA as a 'messy' agent that increases serotonin, dopamine and noradrenaline and acts at serotonin receptor subtypes (references in the text). The methods of the narrative review itself (search strategy, inclusion criteria for cited studies, risk-of-bias assessment) are not specified in the extracted text, so this appears to be a perspective/hypothesis piece supported by selected prior findings rather than a systematic review.

As this is not a primary trial report, the 'results' consist of findings from earlier studies and the author's synthesis. Key points reported in the text include: - Historical LSD studies produced heterogeneous outcomes. Early uncontrolled studies reported abstinence rates in the range of about 30%–50%, while some randomised comparisons found no significant differences between groups or lacked durable improvements. A later pooled analysis of randomised LSD trials from the 1950s–60s (meta-analysis cited in the text) reportedly found generally favourable results, with 59% of LSD-treated participants significantly improved versus 38% of controls. - Ketamine-assisted psychotherapy research from Russia in the 1990s is reported in the text as placebo-controlled studies involving more than 1,000 patients, with ketamine psychotherapy producing total abstinence for more than one year in 66% (the extracted sentence is truncated; this is the figure reported in the paper's text). - There are, according to the extracted text, no published studies to date that formally evaluate MDMA-assisted psychotherapy for any substance use disorder. The author is undertaking a safety and feasibility study (BIMA) as described in the Methods summary. - The paper summarises MDMA's acute physiological and subjective effects reported in clinical contexts: acute increases in blood pressure, heart rate and body temperature; jaw tightness, bruxism and reduced appetite; and in some cases transient increases in anxiety or derealisation-type experiences. Contemporary controlled studies are reported in the text as failing to show significant long-term neurotoxicity associated with recreational MDMA when controlling for other drug use, and the author states that there have been no reports of long-term neurotoxicity or persistent neurocognitive impairments when pure MDMA has been administered in controlled scientific studies. - The author highlights clinical tolerability advantages of MDMA relative to classical psychedelics: MDMA is described as producing fewer perceptual disturbances and being more readily tolerated by some patients, which may be important for adherence in addiction treatment. The paper also notes anecdotal differences in public narratives—many anecdotes exist for LSD/psilocybin helping with AUD, whereas such anecdotes are scarce for ecstasy/MDMA.

The author interprets the evidence as supporting further exploration of MDMA-assisted psychotherapy for alcohol use disorder. The core argument is that MDMA's psychopharmacological effects—reducing fear and defensiveness while permitting engagement with difficult memories—could enhance psychotherapeutic work, particularly for patients whose drinking is linked to past psychological trauma. Compared with classical psychedelics, MDMA is described as more tolerable for some patients because it typically produces fewer perceptual or 'mystical' effects, which may aid compliance in addiction treatment. The author situates these arguments against prior research showing mixed but promising effects of classical psychedelics for alcohol problems and positive findings for ketamine in some historical studies. At the same time, the paper acknowledges important uncertainties: there is no scientific consensus on MDMA's detailed pharmacology and how that maps onto psychological mechanisms; early psychedelic studies were heterogeneous; and, crucially, there are no published clinical trials of MDMA for substance use disorders to provide direct evidence of efficacy. Safety considerations are discussed candidly. Acute physiological effects and transient adverse subjective reactions can occur and must be monitored; however, the author notes that controlled clinical administration of pure MDMA has not been associated with demonstrated long-term neurotoxicity in contemporary studies (as reported in the extracted text). Broader challenges identified by the author include regulatory barriers due to MDMA's schedule-one status, political and media-driven stigma, and funding constraints that increase the cost and difficulty of conducting academic research. The author argues these external obstacles must not prevent rigorous clinical investigation. The paper concludes that, given the persistent burden of AUD and limitations of current treatments, it is timely and necessary to explore innovative options such as MDMA-assisted psychotherapy. The author presents the planned BIMA safety and feasibility study as a first step to generate clinical data in a detoxified, alcohol-dependent population.

The author concludes that MDMA-assisted psychotherapy merits clinical investigation for alcohol use disorder. The planned BIMA study will enrol recently detoxified, alcohol-dependent participants into an 8-week psychotherapy course with two open-label MDMA-assisted sessions (125 mg with a 62.5 mg booster two hours later), close physiological and psychological monitoring during and after sessions, overnight observation, and follow-up to 9 months with outcomes including safety, quality of life, mental and physical health, and drinking behaviours. The author stresses that while MDMA carries cultural controversy due to recreational use, clinical MDMA in controlled settings appears demonstrably safe and may provide therapeutic benefit; regulatory and political obstacles remain significant barriers to research and must be addressed to allow progress.